11 Fastest Growing Penny Stocks to Buy Right Now

Page 4 of 10

7. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $6 from $4 previously and maintained a Buy rating following the company’s fourth-quarter report. H.C. Wainwright increased the probability of success for pilavapadin to 30% from 15% and said the program could attract an “important partnership” as Lexicon’s clinical and regulatory progress helps de-risk the Phase 3-ready asset.

On March 5, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported fourth-quarter EPS of (4c) compared with consensus estimates of (7c). Revenue totaled $5.5 million versus the consensus of $3.14 million. As of December 31, 2025, the company held $125.2 million in cash, investments, and restricted cash, down from $238.0 million in cash and investments as of December 31, 2024. Chief Executive Officer Mike Exton said that the fourth quarter capped “an incredible year” for the company as it advanced pipeline programs, established development and commercialization agreements with global collaborators, and worked with regulators while maintaining operational efficiency. Mike Exton has added that the company entered 2026 with momentum and multiple upcoming catalysts.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat human disease.

Page 4 of 10